We dream big by thinking small, at the cellular level, inventing ways to destroy cancer and advance humanity.

Reimagining cell therapy

Powered by our novel D-Domain technology and paired with our transformative ddCAR and ARC-SparX platforms, our unique approach to cell therapy aims to supercharge how the world treats cancer.

Our Technology

with every cell of our being

From the very beginning, our team has been united to destroy cancer and challenge convention—while ensuring patients stay at the forefront.

Our Company

Mission-critical collaboration

Every day, we are building a more purposeful, empathetic team ready to work together to spearhead change and transform the fight against cancer. Join us.

Culture & Careers

Our Pipeline

Scientific Publications

Latest News

Arcellx Appoints Olivia Ware to Board of Directors

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Contact Us

Sign up for updates

Stay at the forefront of our advancements
in the battle against cancer.

*Required field

By clicking SUBMIT, you agree to our Terms & Conditions and Privacy Policy, and to receive information from Arcellx, its affiliates, service providers, and co-promotion partners.